KR100418327B1 - 신규의 아지리딘 유도체 및 그 제조방법 - Google Patents
신규의 아지리딘 유도체 및 그 제조방법 Download PDFInfo
- Publication number
- KR100418327B1 KR100418327B1 KR10-2001-0021138A KR20010021138A KR100418327B1 KR 100418327 B1 KR100418327 B1 KR 100418327B1 KR 20010021138 A KR20010021138 A KR 20010021138A KR 100418327 B1 KR100418327 B1 KR 100418327B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- general formula
- protecting group
- alkyl
- Prior art date
Links
- 150000001541 aziridines Chemical class 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title description 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 13
- 125000006239 protecting group Chemical group 0.000 claims abstract description 12
- -1 9-fluorenylmethyloxycarbonyl Chemical group 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 50
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000004593 Epoxy Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- XOCUXOWLYLLJLV-UHFFFAOYSA-N [O].[S] Chemical group [O].[S] XOCUXOWLYLLJLV-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 5
- 239000001257 hydrogen Substances 0.000 abstract description 5
- 125000003118 aryl group Chemical group 0.000 abstract description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract description 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 abstract description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000543 intermediate Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- IFXKVICZJOJDGQ-VYAYZGMFSA-N tert-butyl (2S)-2-[(2S)-3-aminooxiran-2-yl]-3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)[C@@H](Cc1ccccc1)[C@@H]1OC1N IFXKVICZJOJDGQ-VYAYZGMFSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 108010010369 HIV Protease Proteins 0.000 description 5
- ZEEOVZCLSBTDKP-IRXDYDNUSA-N benzyl n-[(2r,3r)-3,4-dihydroxy-1-phenylsulfanylbutan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)CO)NC(=O)OCC=1C=CC=CC=1)SC1=CC=CC=C1 ZEEOVZCLSBTDKP-IRXDYDNUSA-N 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- PDSVKWRSGNAHMW-OALUTQOASA-N benzyl n-[(1r)-1-[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-phenylsulfanylethyl]carbamate Chemical compound O1C(C)(C)OC[C@H]1[C@@H](NC(=O)OCC=1C=CC=CC=1)CSC1=CC=CC=C1 PDSVKWRSGNAHMW-OALUTQOASA-N 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 239000004459 forage Substances 0.000 description 4
- 239000004030 hiv protease inhibitor Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- SIFKOOILPFBRCJ-STQMWFEESA-N tert-butyl n-[(2s,3r)-3,4-dihydroxy-1-phenylbutan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]([C@@H](O)CO)CC1=CC=CC=C1 SIFKOOILPFBRCJ-STQMWFEESA-N 0.000 description 4
- 229940122440 HIV protease inhibitor Drugs 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241001442129 Myosotis Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- NVPOUMXZERMIJK-STQMWFEESA-N tert-butyl n-[(1s)-1-[(2r)-oxiran-2-yl]-2-phenylethyl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@H]1OC1)C1=CC=CC=C1 NVPOUMXZERMIJK-STQMWFEESA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- PTFJNZDQRVPSQX-DLBZAZTESA-N benzyl n-[(1r)-1-[(2s)-oxiran-2-yl]-2-phenylsulfanylethyl]carbamate Chemical compound C([C@H](NC(=O)OCC=1C=CC=CC=1)[C@@H]1OC1)SC1=CC=CC=C1 PTFJNZDQRVPSQX-DLBZAZTESA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 2
- VVKBYSVKLPTEON-UWVGGRQHSA-N (2s,3s)-3-(2-phenylethyl)oxiran-2-amine Chemical compound N[C@H]1O[C@H]1CCC1=CC=CC=C1 VVKBYSVKLPTEON-UWVGGRQHSA-N 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- CIWBSHSKHKDKBQ-MVHIGOERSA-N D-ascorbic acid Chemical compound OC[C@@H](O)[C@@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-MVHIGOERSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUFZWUBNVYPAFS-UWVGGRQHSA-N N[C@@H]1[C@H](CCSC2=CC=CC=C2)O1 Chemical compound N[C@@H]1[C@H](CCSC2=CC=CC=C2)O1 GUFZWUBNVYPAFS-UWVGGRQHSA-N 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- IWCVDCOJSPWGRW-UHFFFAOYSA-M magnesium;benzene;chloride Chemical compound [Mg+2].[Cl-].C1=CC=[C-]C=C1 IWCVDCOJSPWGRW-UHFFFAOYSA-M 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N p-toluenesulfonyl chloride Substances CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (8)
- 하기 일반식(Ia) 또는 (Ib)로 표시되는 신규의 아지리딘 유도체:(Ia) (Ib)상기식에서, R2및 R3는 같거나 다르고 각각 C1-C6저급 알킬이며; R4는 아미노 보호기이다.
- 제 1 항에 있어서, 아미노 보호기는 t-부톡시카르보닐, 벤질옥시카르보닐, CH3-Ph-SO2-, (Ph)3C, 및 FMOC(9-플루오레닐메틸옥시카르보닐)로 구성되는 그룹으로부터 선택되는 것을 특징으로 하는 아지리딘 유도체.
- 제 1 항 또는 제 2 항에 있어서, R4는 t-부톡시카르보닐인 것을 특징으로 하는 아지리딘 유도체.
- (a) R2및 R3는 같거나 다르고 각각 C1-C6저급 알킬인, 하기 일반식(1a) 또는 (1b)의 에폭시 화합물을 NaN3와 반응시켜 R2및 R3가 상기한 바와 같은 하기 일반식 (2a) 또는 (2b)의 1-아지도-2-히드록시-3,4-이소프로필리덴부탄 -2,3,4-트리올 유도체를 얻고;(1a) (1b)(2a) (2b)(b) R2및 R3가 상기한 바와 같은 상기 일반식(2a) 또는 (2b)의 화합물을 다시 아민 고리로 만들고 아미노 보호기로 보호화하여 R2및 R3는 상기한 바와 같고 R4는 아미노 보호기인 하기 일반식(I)의 아지리딘 유도체를 제조하는 것을 특징으로 하는(Ia) (Ib)상기 일반식 (Ia) 또는 (Ib)의 아지리딘 유도체의 제조방법.
- 제 4 항에 있어서, 아미노 보호기는 t-부톡시카르보닐, 벤질옥시카르보닐, CH3-Ph-SO2-, (Ph)3C, 및 FMOC(9-플루오레닐메틸옥시카르보닐)로 구성되는 그룹으로부터 선택되는 것을 특징으로 하는 제조방법.
- (a) R2및 R3는 같거나 다르고 각각 각각 C1-C6저급 알킬이며; R4는 아미노 보호기인 하기 일반식(I)의 화합물에, R1은 페닐; 할로겐 원자, 알킬 , 알콕시, R이 알킬을 나타내는 ROCOCH2O-, 또는 벤질옥시 치환기를 갖는 페닐; 페닐티오, 알킬티오; 질소, 산소 황 원자의 하나 이상을 포함하는 헤테로 아릴; 사이클로알킬; 알킬 치환기를 갖는 사이클로알킬; 탄소수 4 이하의 알킬 또는 알케닐; 페닐 또는 OC4H6N-(CH2)2-Ph-치환기를 갖는 알케닐; 질소 및/또는 산소를 포함하는 헤테로 고리; 알킬 치환기를 갖는 질소 및/또는 산소를 포함하는 헤테로 고리로 구성된 그룹으로부터 선택된 R1치환기를 부가하는 반응으로 R1, R2, R3및 R4가 상기한 바와 같은 하기 일반식(6)의 화합물을 제조하고;(I) (6)(b) R1, R2, R3및 R4가 상기한 바와 같은 상기 일반식(6)의 화합물을 히드록실 보호기를 제거하여 R1, R2, R3및 R4가 상기한 바와 같은 하기 일반식(7)의 화합물을 얻은 다음;(7)(c) R1, R2, R3및 R4가 상기한 바와 같은 상기 일반식(7)의 화합물을 에폭시화 반응시켜 R1, R2, R3및 R4가 상기한 바와 같은 하기 일반식(II)의 아지리딘 유도체를 얻는 것을 특징으로 하는(II)상기 일반식(II)의 아지리딘 유도체의 제조방법.
- 제 6 항에 있어서, R1은 페닐 또는 페닐티오 그룹인 것을 특징으로 하는 방법.
- 제 6 항에 있어서, 상기 일반식(I)의 화합물은(a) R2및 R3는 같거나 다르고 각각 C1-C6저급 알킬인, 하기 일반식(1a) 또는 (1b)의 에폭시 화합물을 NaN3와 반응시켜 R2및 R3가 상기한 바와 같은 하기 일반식 (2a) 또는 (2b)의 1-아지도-2-히드록시-3,4-이소프로필리덴부탄 -2,3,4-트리올 유도체를 얻고;(1a) (1b)(2a) (2b)(b) R2및 R3가 상기한 바와 같은 상기 일반식(2a) 또는 (2b)의 화합물을 다시 아민 고리로 만들고 아미노 보호기로 보호화하는 단계에 의해 제조되는 것을 특징으로 하는 방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0021138A KR100418327B1 (ko) | 2001-04-19 | 2001-04-19 | 신규의 아지리딘 유도체 및 그 제조방법 |
US10/473,259 US7049447B2 (en) | 2001-04-19 | 2002-04-19 | Aziridine derivatives and their preparation methods |
PCT/KR2002/000713 WO2002085893A1 (en) | 2001-04-19 | 2002-04-19 | New aziridine derivatives and their preparation methods |
US11/388,883 US20060167277A1 (en) | 2001-04-19 | 2006-03-24 | New aziridine derivatives and their preparation methods |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0021138A KR100418327B1 (ko) | 2001-04-19 | 2001-04-19 | 신규의 아지리딘 유도체 및 그 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020081771A KR20020081771A (ko) | 2002-10-30 |
KR100418327B1 true KR100418327B1 (ko) | 2004-02-11 |
Family
ID=36697805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0021138A KR100418327B1 (ko) | 2001-04-19 | 2001-04-19 | 신규의 아지리딘 유도체 및 그 제조방법 |
Country Status (3)
Country | Link |
---|---|
US (2) | US7049447B2 (ko) |
KR (1) | KR100418327B1 (ko) |
WO (1) | WO2002085893A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4717616B2 (ja) * | 2005-12-07 | 2011-07-06 | ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー | 超音波診断装置 |
KR101103388B1 (ko) * | 2010-12-22 | 2012-01-05 | 에버에스티 주식회사 | 블록형 합성목재 난간대 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100339831B1 (ko) * | 1999-08-18 | 2002-06-07 | 김태성 | 신규의 에틸 아지리딘 유도체 및 그 제조방법 |
-
2001
- 2001-04-19 KR KR10-2001-0021138A patent/KR100418327B1/ko active IP Right Grant
-
2002
- 2002-04-19 US US10/473,259 patent/US7049447B2/en not_active Expired - Lifetime
- 2002-04-19 WO PCT/KR2002/000713 patent/WO2002085893A1/en not_active Application Discontinuation
-
2006
- 2006-03-24 US US11/388,883 patent/US20060167277A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20020081771A (ko) | 2002-10-30 |
US7049447B2 (en) | 2006-05-23 |
US20040097480A1 (en) | 2004-05-20 |
US20060167277A1 (en) | 2006-07-27 |
WO2002085893A1 (en) | 2002-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20110598L (no) | Karbonatforbindelser | |
EP2528923B1 (en) | Process for the preparation of darunavir and darunavir intermediates | |
JP5593342B2 (ja) | ドセタキセルの製造方法 | |
FI120259B (fi) | Menetelmä epoksidin valmistamiseksi | |
CN109020992B (zh) | 一种立体选择性制备β型单/双青蒿烷基醚胺马来酸盐的方法 | |
RU2470018C2 (ru) | Новые производные пирокатехина | |
KR100418327B1 (ko) | 신규의 아지리딘 유도체 및 그 제조방법 | |
KR100847331B1 (ko) | 도세탁셀의 제조방법 및 이에 사용되는 중간체 | |
KR20030082946A (ko) | 1,2-벤즈이속사졸-3-아세트산의 제조 방법 | |
KR100344478B1 (ko) | 에폭사이드로부터시스-1-아미노-2-알칸올을제조하는부분특이적방법 | |
JP2002512603A (ja) | 医薬化合物の製造方法 | |
EP0930291B1 (en) | Process for the preparation of 3-amino-2-hydroxy-1-propyl ethers | |
EP3986400B1 (en) | Processes and intermediates for producing diazaspiro lactam compounds | |
US6348484B1 (en) | Stereoisomeric indole compounds, process for the preparation of the same, and use thereof | |
ES2715503T3 (es) | Un nuevo método de producción de clorhidrato de nebivolol de alta pureza | |
ES2912409T3 (es) | Intermedios y procesos para la preparación de linagliptina y sus sales | |
JP2017014199A (ja) | 新規なヒドロキサム酸誘導体の製造方法 | |
WO2004002973A1 (ja) | 光学活性1−置換アミノー2,3−エポキシプロパンの製造方法並びにその合成中間体およびそれらの製造方法 | |
JP2007521277A (ja) | 化合物の製造 | |
US6573388B1 (en) | Ethylaziridine derivatives and their preparation methods | |
US10519098B2 (en) | Aromatic derivatives as anti-malarial | |
CN114230630B (zh) | 雷公藤甲素衍生物及其应用 | |
Paulvannan et al. | Asymmetric Synthesis of Mercaptoalcohols-Matrix Metalloproteinase Inhibitors | |
KR100566896B1 (ko) | 광학적으로 활성인 5,6-디옥소피페라진-2-카르복실산유도체의 제조방법 | |
KR960011580B1 (ko) | 비가역적 에이치아이브이(hiv) 프로테아제 억제제의 중간체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130129 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140129 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20150128 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20160128 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20170124 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20180119 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20190109 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20200122 Year of fee payment: 17 |